⏳ Fetching live dividend data...
Home › Calculator › OCX Dividend Calculator 2026
OncoCyte Corporation · NASDAQ
Price: $3.20 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in OCX → $11726587531.85M in 10 years · $975,691,110,294,140.60/month
OncoCyte Corporation is a molecular diagnostics firm that conceptualizes, refines, and brings to market its exclusive laboratory-developed tests aimed at identifying cancer in patients, serving both the United States and global markets. The company's portfolio features DetermaRx, a specialized molecular test for detecting early-stage adenocarcinoma in the lung, alongside DetermaIO, a unique proprietary assay that assesses gene expression. In addition to its diagnostic offerings, OncoCyte provides a suite of services including biomarker discovery, the design and development of new assays, and essential support for clinical trials. It also delivers various biomarker testing solutions specifically tailored for pharmaceutical companies. OncoCyte has established a collaborative agreement with Life Technologies Corporation. This partnership is geared towards the co-development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, which are designed for use with the Ion Torrent Genexus integrated sequencer and purification system. The corporation was founded in 2009 and its primary base of operations is situated in Irvine, California.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open OCX position with:
Real after-tax yield depends on where you live and how you hold OCX.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 62.50% | 59.70% | $6,250 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 53.13% | 50.33% | $5,313 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 50.00% | 47.20% | $5,000 / yr |
| 🇬🇧 UK ISA | 0% | 62.50% | 59.70% | $6,250 / yr |
| 🇬🇧 UK Taxable | 8.75% | 57.03% | 54.23% | $5,703 / yr |
| 🇨🇦 TFSA | 0% | 62.50% | 59.70% | $6,250 / yr |
| 🇨🇦 CA Taxable | 25% | 46.88% | 44.08% | $4,688 / yr |
| 🇦🇺 Super (pension) | 15% | 53.13% | 50.33% | $5,313 / yr |
| 🇦🇺 AU Taxable | 30% | 43.75% | 40.95% | $4,375 / yr |
| 🇩🇪 DE Taxable | 26.375% | 46.02% | 43.22% | $4,602 / yr |
| 🇫🇷 FR Taxable | 30% | 43.75% | 40.95% | $4,375 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
OCX pays quarterly — 4 times per year. Next ex-div: TBD.
How OCX compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for OCX sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| J-Other | 2023-03-06 | 3,890,111 | — | — |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the OCX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
OncoCyte Corporation (OCX) is currently trading at $3.20, 97% below its 52-week high. The current dividend yield is 62.50% based on an annual payout of $2.00 per share.
OncoCyte Corporation (OCX) is a healthcare stock currently trading at $3.20 with a dividend yield of 62.50%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →